Successful Everolimus Treatment in a Patient with Advanced Pancreatic Neuroendocrine Tumor Who Developed Everolimus-Induced Interstitial Lung Disease on Two Occasions: A Case Report

Publisher： Karger

E-ISSN： 1421-9794|59|1|74-78

ISSN： 0009-3157

Source： Chemotherapy, Vol.59, Iss.1, 2013-07, pp. : 74-78

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-Term Everolimus Treatment of Patients with Pancreatic Neuroendocrine Tumors

By  

Chemotherapy, Vol. 60, Iss. 3, 2015-03 ,pp. : 143-150

Karger

Access to resources Recommend Favorite

Rituximab-Induced Interstitial Lung Disease: Case Report and Literature Review

By  

Pharmacology, Vol. 87, Iss. 5-6, 2011-05 ,pp. : 318-320

Karger

Access to resources Recommend Favorite

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

By Bendtsen Mathias Alrø Fichtner   Grimm Daniela   Bauer Johann   Wehland Markus   Wise Petra   Magnusson Nils E.   Infanger Manfred   Krüger Marcus  

International Journal of Molecular Sciences, Vol. 18, Iss. 8, 2017-08 ,pp. : 1736-1736

MDPI

Access to resources Recommend Favorite

Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future

By Ohmoto Akihiro   Rokutan Hirofumi   Yachida Shinichi  

International Journal of Molecular Sciences, Vol. 18, Iss. 1, 2017-01 ,pp. : 143-143

MDPI

Access to resources Recommend Favorite

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

By Wu Wen-Shuo   Chen Yuh-Min  

Journal of Personalized Medicine, Vol. 4, Iss. 3, 2014-06 ,pp. : 297-310

MDPI

Access to resources Recommend Favorite